U.S. drug regulators approved a new customized, cell-based treatment for blood cancer from Johnson & Johnson that is the first such therapy in the U.S. to be developed initially in China.
The Food and Drug Administration on Monday cleared the therapy, named Carvykti, for the treatment of multiple myeloma in adult patients whose disease has worsened despite prior treatments with other drugs.
RichaSh67308719
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: